RO 6958688

Drug Profile

RO 6958688

Alternative Names: CEA-CD3 TCB; CEA-TCB; RG-7802; RO-6958688

Latest Information Update: 01 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action Carcinoembryonic antigen inhibitors; CD3 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Non-small cell lung cancer
  • Phase I Solid tumours

Most Recent Events

  • 17 Nov 2017 Roche plans a phase I/II trial for Non-small cell lung cancer (Combination therapy, Metastatic disease) in Australia, South Korea, France, Spain, United Kingdom and USA in December 2017 (NCT03337698)
  • 14 Nov 2017 Phase-I/II clinical trials in Non-small cell lung cancer (Combination therapy, Metastatic disease) in Australia (IV) (NCT03337698)
  • 09 Nov 2017 Chugai plans a phase I trial for Solid tumours (Late-stage disease, Monotherapy, Combination therapy, Second-line therapy or greater) in Japan (JapicCTI-173764)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top